{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=acalabrutinib&page=2", "query": { "intervention": "acalabrutinib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 127, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=acalabrutinib&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=acalabrutinib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T00:06:45.602Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04529772", "title": "A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "acalabrutinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 611, "start_date": "2020-10-08", "completion_date": "2027-02-22", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-04T00:06:45.602Z", "location_count": 32, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Norwich", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04529772" }, { "nct_id": "NCT07257055", "title": "Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Phase 2 Study", "MCL", "BTKi", "Rituximab", "Glofitamab" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Glofitamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-04-01", "completion_date": "2030-11-24", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-04T00:06:45.602Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07257055" }, { "nct_id": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, B-Cell", "Small Lymphocytic Lymphoma", "Chronic Lymphocytic Leukemia", "Waldenstrom Macroglobulinemia", "Mantle Cell Lymphoma", "Diffuse Large B Cell Lymphoma", "Richter's Transformation", "Follicular Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Nemtabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2017-06-26", "completion_date": "2027-09-17", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-04T00:06:45.602Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03162536" }, { "nct_id": "NCT03968848", "title": "Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Impairment", "Hepatic Insufficiency", "Healthy Subjects" ], "interventions": [ { "name": "acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 16, "start_date": "2018-11-12", "completion_date": "2019-03-29", "has_results": true, "last_update_posted_date": "2021-09-10", "last_synced_at": "2026-10-04T00:06:45.602Z", "location_count": 3, "location_summary": "Miami, Florida • Orlando, Florida • Knoxville, Tennessee", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03968848" }, { "nct_id": "NCT04624633", "title": "Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Relapsed Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Umbralisib", "type": "DRUG" }, { "name": "Ublituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jennifer R. Brown, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2020-12-15", "completion_date": "2028-01-01", "has_results": true, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-10-04T00:06:45.602Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04624633" }, { "nct_id": "NCT05065554", "title": "ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgM MGUS", "Waldenstrom Macroglobulinemia", "Neuropathy;Peripheral" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shayna Sarosiek, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2021-11-16", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-10-04T00:06:45.602Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05065554" }, { "nct_id": "NCT04435483", "title": "A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics", "Bioavailability" ], "interventions": [ { "name": "Acalabrutinib Treatment A", "type": "DRUG" }, { "name": "Acalabrutinib Treatment B", "type": "DRUG" }, { "name": "Acalabrutinib Treatment C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 39, "start_date": "2020-05-22", "completion_date": "2020-06-26", "has_results": false, "last_update_posted_date": "2020-07-22", "last_synced_at": "2026-10-04T00:06:45.602Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04435483" }, { "nct_id": "NCT02537444", "title": "Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "acalabrutinib and pembrolizumab combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 78, "start_date": "2015-11", "completion_date": "2018-10", "has_results": true, "last_update_posted_date": "2019-09-25", "last_synced_at": "2026-10-04T00:06:45.602Z", "location_count": 2, "location_summary": "Tucson, Arizona • Philadelphia, Pennsylvania", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02537444" }, { "nct_id": "NCT05388006", "title": "Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Richter Syndrome", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography (PET)", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2023-01-05", "completion_date": "2027-02-22", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-10-04T00:06:45.602Z", "location_count": 3, "location_summary": "Palo Alto, California • Rochester, Minnesota • St Louis, Missouri", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05388006" }, { "nct_id": "NCT02180711", "title": "Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "acalabrutinib", "type": "DRUG" }, { "name": "rituximab (IV)", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2014-12-29", "completion_date": "2028-12-11", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-04T00:06:45.602Z", "location_count": 23, "location_summary": "Tucson, Arizona • Downey, California • Duarte, California + 18 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02180711" } ] }